{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:08:56Z","timestamp":1794830936813,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007258","name":"State University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DBI 0923133"],"award-info":[{"award-number":["DBI 0923133"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01EB019411-01A1"],"award-info":[{"award-number":["1R01EB019411-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.omtn.2023.02.031","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T11:45:59Z","timestamp":1677584759000},"page":"36-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment"],"prefix":"10.1016","volume":"32","author":[{"given":"Lingyue","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vui King","family":"Vincent-Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfrido","family":"Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukund","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruogang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-777X","authenticated-orcid":false,"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.omtn.2023.02.031_bib1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1513\/AnnalsATS.201410-448MG","article-title":"Mechanisms of alveolar epithelial injury, repair, and fibrosis","volume":"12","author":"Chambers","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.omtn.2023.02.031_bib2","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/S1357-2725(02)00091-2","article-title":"Idiopathic pulmonary fibrosis: new insights in its pathogenesis","volume":"34","author":"Pardo","year":"2002","journal-title":"IntInt. J. Biochem. Cell Biol."},{"key":"10.1016\/j.omtn.2023.02.031_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00170-2018","article-title":"Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry","volume":"5","author":"Kaunisto","year":"2019","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.omtn.2023.02.031_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","volume":"9","author":"Wolters","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omtn.2023.02.031_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/ph14080807","article-title":"Lung fibrosis after COVID-19: treatment prospects","volume":"14","author":"Bazdyrev","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2023.02.031_bib6","doi-asserted-by":"crossref","first-page":"190021","DOI":"10.1183\/16000617.0021-2019","article-title":"The therapy of idiopathic pulmonary fibrosis: what is next?","volume":"28","author":"Somogyi","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.omtn.2023.02.031_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.omtn.2023.02.031_bib8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.omtn.2023.02.031_bib9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.02.031_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.apsb.2016.06.010","article-title":"MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics","volume":"6","author":"Li","year":"2016","journal-title":"Acta Pharm. Sin. B B"},{"key":"10.1016\/j.omtn.2023.02.031_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.omtn.2023.02.031_bib12","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1073\/pnas.0805038105","article-title":"Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis","volume":"105","author":"Van Rooij","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.02.031_bib13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","article-title":"Smad3-mediated upregulation of miR-21 promotes renal fibrosis","volume":"22","author":"Zhong","year":"2011","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2023.02.031_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1681\/ASN.2010020134","article-title":"miR-192 mediates TGF-beta\/Smad3-driven renal fibrosis","volume":"21","author":"Chung","year":"2010","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2023.02.031_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molmed.2011.01.006","article-title":"MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer","volume":"17","author":"Andorfer","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtn.2023.02.031_bib16","first-page":"188","article-title":"The mir-15a\/mir-16-1 cluster controls prostate cancer progression control by targeting of multiple oncogenic activities","volume":"181","author":"Bonci","year":"2009","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.omtn.2023.02.031_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death DifferCell Death Differ."},{"key":"10.1016\/j.omtn.2023.02.031_bib18","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","article-title":"MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells","volume":"4","author":"Ji","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.02.031_bib19","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/ndt\/gfx367","article-title":"Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes","volume":"33","author":"Roux","year":"2018","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.omtn.2023.02.031_bib20","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2337\/db11-0478","article-title":"miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications","volume":"60","author":"Feng","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2023.02.031_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00125-012-2804-x","article-title":"miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes","volume":"56","author":"Zhong","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.omtn.2023.02.031_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1465-9921-14-95","article-title":"The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells","volume":"14","author":"Yamada","year":"2013","journal-title":"RespirRespir. Res."},{"key":"10.1016\/j.omtn.2023.02.031_bib23","doi-asserted-by":"crossref","first-page":"L534","DOI":"10.1152\/ajplung.00149.2013","article-title":"Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts","volume":"306","author":"Huleihel","year":"2014","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.omtn.2023.02.031_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ajpath.2011.10.005","article-title":"Participation of miR-200 in pulmonary fibrosis","volume":"180","author":"Yang","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2023.02.031_bib25","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/mt.2014.42","article-title":"The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis","volume":"22","author":"Liang","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.02.031_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbrc.2014.10.106","article-title":"MicroRNA-26a modulates transforming growth factor beta-1-induced proliferation in human fetal lung fibroblasts","volume":"454","author":"Li","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2023.02.031_bib27","doi-asserted-by":"crossref","first-page":"e1238","DOI":"10.1038\/cddis.2014.207","article-title":"Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis","volume":"5","author":"Liang","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2023.02.031_bib28","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1093\/nar\/gks1460","article-title":"miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt\/beta-catenin pathway","volume":"41","author":"Wang","year":"2013","journal-title":"Nucleic Acids ResNucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.02.031_bib29","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1038\/s41598-017-11904-8","article-title":"MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1","volume":"7","author":"Yan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.02.031_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ymthe.2016.12.017","article-title":"miR-18a-5p inhibits sub-pleural pulmonary fibrosis by targeting TGF-beta receptor II","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.02.031_bib31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20100035","article-title":"miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis","volume":"207","author":"Liu","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2023.02.031_bib32","doi-asserted-by":"crossref","first-page":"e6718","DOI":"10.1371\/journal.pone.0006718","article-title":"Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions","volume":"4","author":"Pottier","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.02.031_bib33","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.jaci.2016.09.021","article-title":"The role of microRNA-155\/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis","volume":"139","author":"Kurowska-Stolarska","year":"2017","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2023.02.031_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1165\/rcmb.2015-0205OC","article-title":"MicroRNA-27a-3p is a negative regulator of lung fibrosis by targeting myofibroblast differentiation","volume":"54","author":"Cui","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.omtn.2023.02.031_bib35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/mt.2012.36","article-title":"miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice","volume":"20","author":"Xiao","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.02.031_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2023.02.031_bib37","doi-asserted-by":"crossref","first-page":"L632","DOI":"10.1152\/ajplung.00127.2014","article-title":"MicroRNA-96 inhibits FoxO3a function in IPF fibroblasts on type I collagen matrix","volume":"307","author":"Nho","year":"2014","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.omtn.2023.02.031_bib38","doi-asserted-by":"crossref","first-page":"16420","DOI":"10.1074\/jbc.M117.805747","article-title":"MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation","volume":"292","author":"Huang","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.02.031_bib39","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1165\/rcmb.2013-0195OC","article-title":"MicroRNA-326 regulates profibrotic functions of transforming growth factor-beta in pulmonary fibrosis","volume":"50","author":"Das","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.omtn.2023.02.031_bib40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.15252\/embr.201540750","article-title":"miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2","volume":"16","author":"Fierro-Fern\u00e1ndez","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2023.02.031_bib41","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/jcp.26961","article-title":"Downregulation of microRNA-9 reduces inflammatory response and fibroblast proliferation in mice with idiopathic pulmonary fibrosis through the ANO1-mediated TGF-beta-Smad3 pathway","volume":"234","author":"Dai","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtn.2023.02.031_bib42","article-title":"MiR-185\/AKT and miR-29a\/collagen 1a pathways are activated in IPF alveolar macrophages","volume":"48","author":"Tsitoura","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.omtn.2023.02.031_bib43","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1038\/ncomms9523","article-title":"miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program","volume":"6","author":"Su","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.02.031_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/ijms18030633","article-title":"miR-30a as potential therapeutics by targeting TET1 through regulation of Drp-1 promoter hydroxymethylation in idiopathic pulmonary fibrosis","volume":"18","author":"Zhang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2023.02.031_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00109-016-1381-8","article-title":"miR-26a suppresses EMT by disrupting the Lin28B\/let-7d axis: potential cross-talks among miRNAs in IPF","volume":"94","author":"Liang","year":"2016","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.omtn.2023.02.031_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3747\/co.v16i4.486","article-title":"RNA interference and micro-RNA-oriented therapy in cancer: rationales, promises, and challenges","volume":"16","author":"Duchaine","year":"2009","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.omtn.2023.02.031_bib47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12195-019-00590-3","article-title":"Cyclic stretching of fibrotic microtissue array for evaluation of anti-fibrosis drugs","volume":"12","author":"Asmani","year":"2019","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.omtn.2023.02.031_bib48","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41467-018-04336-z","article-title":"Fibrotic microtissue array to predict anti-fibrosis drug efficacy","volume":"9","author":"Asmani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.02.031_bib49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.omtn.2023.02.031_bib50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41467-020-20449-w","article-title":"Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation","volume":"12","author":"Bobba","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.02.031_bib51","doi-asserted-by":"crossref","first-page":"14131","DOI":"10.1038\/srep14131","article-title":"The anti-fibrotic effects and mechanisms of MicroRNA-486-5p in pulmonary fibrosis","volume":"5","author":"Ji","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.02.031_bib52","first-page":"517","article-title":"EMT and interstitial lung disease: a mysterious relationship","volume":"18","author":"Kage","year":"2012","journal-title":"Curr. Opin. Pulm. Med."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:12:39Z","timestamp":1730736759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":52,"alternative-id":["S2162253123000513"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.02.031","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}